A mult institutional phase II trial of neoadjuvant capecitabine (Xeloda) and oxaliplatin Eloxatin) for resectable colorectal metastases in the liver

Trial Profile

A mult institutional phase II trial of neoadjuvant capecitabine (Xeloda) and oxaliplatin Eloxatin) for resectable colorectal metastases in the liver

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2013

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Cancer metastases; Colorectal cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 06 Mar 2008 New trial record.
    • 01 Sep 2004 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top